Interaction of terbinafine with human serum and serum proteins

REFERENCES

• Bergan T., Engeset A., Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics. Reviews of Infectious Diseases 1987; 9: 713–718
   PubMedGoogle Scholar
• Burstein M., Scholnick H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Journal of Lipid Research 1970; 11: 583–595
   PubMed Web of Science ®Google Scholar
• Gotto A.M., Pownall H.J., Havel R.J. Introduction to the plasma lipoproteins. Methods in Enzymology Vol. 128; Plasma Lipoproteins Part A, J.P. Segrest, J.J. Albers. Academic Press, Orlando, Fl. 1986; 3–41, In
   Google Scholar
• Hull P.R., Vismer H.F. Treatment of cutaneous sporotrichosis with terbinafine. British Journal of Dermatology 1992; 126(Suppl. 39)51–55
   PubMed Web of Science ®Google Scholar
• Jensen J.C. Pharmacokinetics of Lamisil in humans. Journal of Dermatological Treatment 1990; 1(Suppl. 2)15–18
   Google Scholar
• Kan V.L., Bennett J.E. Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrobial Agents and Chemotherapy 1988; 32: 1619–1623
   PubMed Web of Science ®Google Scholar
• Koch-Weser J., Sellers E.M. Binding of drugs to serum albumin. New England Journal of Medicine 1976; 294: 311–316
   PubMed Web of Science ®Google Scholar
• Lemaire M., Tillement J.P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. Journal of Pharmacy and Pharmacology 1982; 34: 715–718
   PubMed Web of Science ®Google Scholar
• Machard B., Misslin P., Lemaire M. Influence of plasma protein binding on the brain uptake of an antifungal agent, terbinafine, in rats. Journal of Pharmacy and Pharmacology 1989; 41: 700–704
   PubMed Web of Science ®Google Scholar
• Mills G.L., Lane P.A., Weech P.K. A Guidebook to Lipoprotein Technique. Elsevier, Amsterdam 1984; 463–471
   Google Scholar
• Petranyi G., Meingassner J.G., Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrobial Agents and Chemotherapy 1987; 31: 1365–1368
   PubMed Web of Science ®Google Scholar
• Petranyi G., Ryder N.S., Stütz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239–1241
   PubMed Web of Science ®Google Scholar
• Petranyi G., Stütz A., Ryder N.S., Meingassner J.G., Mieth H. Experimental antimycotic activity of naftifine and terbinafine. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, R.A. Fromtling. J. R. Prous, Barcelona 1987; 441–450, In
   Google Scholar
• Polak A., Dixon D.M. Chemotherapeutic activity in a mouse model of cryptococcosis with cutaneous and nasal involvement. Mycoses 1988; 31: 501–507
   PubMed Web of Science ®Google Scholar
• Ryder N.S. Effect of allyamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. Journal of General Microbiology 1985; 131: 1595–1602
   PubMedGoogle Scholar
• Ryder N.S. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrobial Agents and Chemotherapy 1985; 27: 252–256
   PubMed Web of Science ®Google Scholar
• Ryder N.S. Biochemical mode of action and enantiomeric selectivity of SDZ 89-485, a new triazole antimycotic. Journal of Medical and Veterinary Mycology 1990; 28: 385–394
   PubMedGoogle Scholar
• Ryder N.S. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. British Journal of Dermatology 1992; 126(Suppl. 39)2–7
   PubMed Web of Science ®Google Scholar
• Ryder N.S., Mieth H. Allylamine antifungal drugs. Current Topics in Medical Mycology, M. Borgers, R. Hay, M.G. Rinaldi. Springer-Verlag, New York 1992; 4: 158–188, In
   Google Scholar
• Ryder N.S., Seidl G., Troke P.F. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrobial Agents and Chemotherapy 1984; 25: 483–487
   PubMed Web of Science ®Google Scholar
• Schmitt H.J., Andrade J., Edwards F., Niki Y., Bernard E., Armstrong D. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. European Journal of Clinical Microbiology and Infectious Diseases 1990; 9: 832–835
   PubMed Web of Science ®Google Scholar
• Schuster I., Schaude M., Schatz F., Mieth H. Preclinical characteristics of allylamines. Sterol Biosynthesis Inhibitors. Pharmaceutical and Agrochemical Aspects, D. Berg, M. Plempel. Ellis Horwood, Chichester 1988; 449–470, In
   Google Scholar
• Tillement J.-P., Houin G., Zini R., Urien S., Albengres E., Barre J., Lecomte M., D'Athis P., Sebille B. The binding of drugs to blood plasma macromolecules: recent advances and therapeutic significance. Advances in Drug Research 1984; 13: 59–94
   Google Scholar
• Villars V.V., Jones T.C. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. British Journal of Dermatology 1992; 129(Suppl. 39)61–69
   Google Scholar